WCN25-4091 OUTCOME OF PRIMARY MEMBRANOUS NEPHROPATHY IN DIABETIC AND NON-DIABETIC PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY
Introduction: Primary focal segmental glomerulosclerosis (FSGS) that does not respond to treatment is likely to progress rapidly to end-stage renal disease.[1] There is limited data available on the use of rituximab in cases that do not respond to treatment.This study was conducted to investigate the effectiveness of rituximab in cases of treatment-resistant FSGS.1. Michelle A. Hladunewich, Dan Cattran, Sanjeev M. Sethi, et al.Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Acti-
Authors
- MANISH CHATURVEDY
- RAJESH JHORAWAT
- E. Louise Thomas (ORCID: https://orcid.org/0000-0003-4235-4694)
Institutions
- All India Institute of Medical Sciences Jodhpur (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.1038
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00